Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches

Open-label, Randomized, Four-treatment, Four-sequence, Four-period, Crossover, Single-application Study Evaluating and Comparing Product Adhesion in Healthy Adult Subjects Using ZTlido 1.8% Versus Salonpas(Lidocaine Patch 4%), Aspercreme(Lidocaine Patch 4%) and IcyHot(Lidocaine 4% + Menthol 1% Patch)

The study is designed to evaluate and compare the clinical adhesion performance of the ZTlido (Lidocaine Topical System) 1.8% of Scilex Pharmaceuticals Inc. (Reference) versus Salonpas (Lidocaine Patch 4%), Aspercreme (Lidocaine Patch 4%) and IcyHot (Lidocaine 4% + Menthol 1% Patch), on the Mid to upper back while being worn for 12 hours in healthy adult human subjects.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: ZTlido (Lidocaine Topical System) 1.8%; Drug: Salonpas (Lidocaine Patch 4%); Drug: Aspercreme (Lidocaine Patch 4%); Drug: IcyHot (Lidocaine 4% + Menthol 1% Patch)

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Dilworth, Minnesota, United States, 56529
      • Axis Clinicals

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy, male and female subjects aged 18 years and older with a Body Mass Index (BMI) range 18.0-32.49 kg/m2 inclusive (according to the formula of BMI = weight (kg) / [height (m)2]).
• Subjects who have no evidence of underlying disease during screening and check-in and whose screening is performed within 28 days of check-in.
• Subjects whose screening laboratory values are within normal limits or considered by the physician or Principal Investigator to be of no clinical significance.
• Absence of disease markers of HIV 1 & 2, hepatitis B & C virus.
• Generally healthy as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory, musculoskeletal and central nervous systems) and vital sign assessments.
• Generally healthy as documented by 12-lead electrocardiogram (ECG), and clinical laboratory assessments.
• Any abnormalities/deviations from the acceptable range of medical history, clinical laboratory values, ECG and vitals, that might be considered clinically relevant by the study physician or investigator will be evaluated as individual cases.
• Subjects able to comply with study procedures, in the opinion of the Principal Investigator.
• Willing to give written consent and adhere to all the requirements of this protocol.
• Female subjects of childbearing potential;
• Non-pregnant and non-lactating females practicing medically acceptable forms of Birth Control and willing to continue during the study.
• Postmenopausal Female- Age > 45 years and Amenorrhea for at least 1 year; or Bilateral Oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months; or Total hysterectomy and an absence of bleeding for at least 3 months.
• Male volunteers must practice protected sex throughout the study.

Exclusion Criteria:

• Evidence of allergy or known hypersensitivity to lidocaine, local anesthetics of the amide type e.g., bupivacaine, etidocaine, mepivacaine and prilocaine or to any of the components of formulation.Any major illness in the last three months or any significant chronic medical illness.
• Subjects with history of addiction, abuse, and misuse of any drug - as per physician discretion.
• Subjects with history of mental illness as per physician discretion.
• Presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, hepatic, dermatologic, musculoskeletal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the Medical Investigator).
• Participation in any clinical trial within 30 days prior to product application.
• Subjects with inflamed or injured skin, such as active herpes zoster lesions, atopic dermatitis or wounds where the product will be placed.
• Presence of any skin condition such as scratches, cuts, scars, abrasions, excessive hair, tattoos, moles, recently shaved skin, uneven skin texture, open sores, irritated (redness, rash, or blisters, etc.) or excessively oily skin at the application areas that may affect the application of the study product.
• Use of make-up, creams, lotions, powders, or other topical products to the skin area where the product will be placed, within 48 hours prior to product application.
• Use of antihistamines at product application site within 72 hours prior to product application.
• Using antiarrhythmic drugs (such as tocainide and mexiletine) and local anesthetics within 14 days prior to product application.
• Radiation therapy within 3 weeks prior to product application
• History of significant dermatologic cancers (e.g., melanoma, squamous cell carcinoma etc.) except basal cell carcinomas that were superficial and did not involve the investigative sites.
• Use of nicotine containing products (including e-cigarettes, patches, gum, chewing tobacco, cigars, etc.) within 30 days prior to patch application.
• Positive results for drugs of abuse and alcohol breath analysis prior to product application.
• Female subjects:
• Demonstrating a positive pregnancy screen
• Who are currently breastfeeding
• Use of hormone replacement therapy within three months prior to product application.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: ZTlido (Lidocaine Topical System) 1.8%	Drug: ZTlido (Lidocaine Topical System) 1.8%; 1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
Other: Salonpas (Lidocaine Patch 4%)	Drug: Salonpas (Lidocaine Patch 4%); 1 Salonpas (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
Other: Aspercreme (Lidocaine Patch 4%)	Drug: Aspercreme (Lidocaine Patch 4%); 1 Aspercreme (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
Other: IcyHot (Lidocaine 4% + Menthol 1% Patch)	Drug: IcyHot (Lidocaine 4% + Menthol 1% Patch); 1 IcyHot (Lidocaine 4% + Menthol 1% Patch) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Percent adhesion	The adhesion performance (i.e., degree of lifting or detachment) is assessed by clinicians at each time point. The adhesion of Test Products 1, 2, and 3 (each over-the-counter external analgesic lidocaine-containing patch) are compared to the adhesion performance observed for the Reference Product.	0, 3, 6, 8, 10, and 12 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events	The number of adverse events observed in each treatment will be used to assess the safety and tolerability of the four interventions	12 hours

Collaborators and Investigators

• Sponsor: Scilex Pharmaceuticals, Inc.
• Investigators: Study Director: Dmitri Lissin, MD, Chief Medical Officer

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2021
• Primary Completion (Actual): July 21, 2021
• Study Completion (Actual): July 21, 2021

Study Registration Dates

• First Submitted: October 11, 2021
• First Submitted That Met QC Criteria: October 22, 2021
• First Posted (Actual): November 3, 2021

Study Record Updates

• Last Update Posted (Actual): November 3, 2021
• Last Update Submitted That Met QC Criteria: October 22, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Fibrosis; Cicatrix; Tissue Adhesions; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Dermatologic Agents; Membrane Transport Modulators; Anesthetics, Local; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Antipruritics; Lidocaine; Menthol
• Other Study ID Numbers: A21.1463

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No